These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17020463)

  • 1. Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme.
    Panner A; Parsa AT; Pieper RO
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1313-22. PubMed ID: 17020463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
    Bjelogrlić SK; Srdić T; Radulović S
    J BUON; 2006; 11(3):267-76. PubMed ID: 17309148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting mTOR for cancer treatment.
    Rubio-Viqueira B; Hidalgo M
    Curr Opin Investig Drugs; 2006 Jun; 7(6):501-12. PubMed ID: 16784020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.
    Eshleman JS; Carlson BL; Mladek AC; Kastner BD; Shide KL; Sarkaria JN
    Cancer Res; 2002 Dec; 62(24):7291-7. PubMed ID: 12499272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [mTOR signal pathway and its inhibitors in antitumor therapy: a review].
    Huang JJ; Lin TY
    Ai Zheng; 2007 Dec; 26(12):1397-403. PubMed ID: 18076811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis.
    Opel D; Westhoff MA; Bender A; Braun V; Debatin KM; Fulda S
    Cancer Res; 2008 Aug; 68(15):6271-80. PubMed ID: 18676851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The biology behind mTOR inhibition in sarcoma.
    Wan X; Helman LJ
    Oncologist; 2007 Aug; 12(8):1007-18. PubMed ID: 17766661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.
    Janus A; Robak T; Smolewski P
    Cell Mol Biol Lett; 2005; 10(3):479-98. PubMed ID: 16217558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential role of mTOR inhibitors in non-small cell lung cancer.
    Gridelli C; Maione P; Rossi A
    Oncologist; 2008 Feb; 13(2):139-47. PubMed ID: 18305058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.
    Huang S; Houghton PJ
    Curr Opin Investig Drugs; 2002 Feb; 3(2):295-304. PubMed ID: 12020063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammalian target of rapamycin inhibitors in sarcomas.
    Okuno S
    Curr Opin Oncol; 2006 Jul; 18(4):360-2. PubMed ID: 16721131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells.
    Panner A; James CD; Berger MS; Pieper RO
    Mol Cell Biol; 2005 Oct; 25(20):8809-23. PubMed ID: 16199861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin: an anti-cancer immunosuppressant?
    Law BK
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):47-60. PubMed ID: 16039868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
    Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
    Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of mTOR in the management of solid tumors: an overview.
    Strimpakos AS; Karapanagiotou EM; Saif MW; Syrigos KN
    Cancer Treat Rev; 2009 Apr; 35(2):148-59. PubMed ID: 19013721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
    Brachmann S; Fritsch C; Maira SM; García-Echeverría C
    Curr Opin Cell Biol; 2009 Apr; 21(2):194-8. PubMed ID: 19201591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR.
    Hou G; Xue L; Lu Z; Fan T; Tian F; Xue Y
    Cancer Lett; 2007 Aug; 253(2):236-48. PubMed ID: 17360108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer.
    Frese S; Schüller A; Frese-Schaper M; Gugger M; Schmid RA
    Anticancer Res; 2009 Aug; 29(8):2905-11. PubMed ID: 19661294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
    Ronellenfitsch MW; Brucker DP; Burger MC; Wolking S; Tritschler F; Rieger J; Wick W; Weller M; Steinbach JP
    Brain; 2009 Jun; 132(Pt 6):1509-22. PubMed ID: 19416948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.